288 related articles for article (PubMed ID: 25921689)
1. Plasma and Intracellular Pharmacokinetics of Tenofovir Disoproxil Fumarate 300 mg Every 48 Hours vs 150 mg Once Daily in HIV-Infected Adults With Moderate Renal Function Impairment.
Cressey TR; Avihingsanon A; Halue G; Leenasirimakul P; Sukrakanchana PO; Tawon Y; Jaisieng N; Jourdain G; Podany AT; Fletcher CV; Klinbuayaem V; Bowonwatanuwong C
Clin Infect Dis; 2015 Aug; 61(4):633-9. PubMed ID: 25921689
[TBL] [Abstract][Full Text] [Related]
2. Efficacy, safety and pharmacokinetics of tenofovir disoproxil fumarate in virologic-suppressed HIV-infected children using weight-band dosing.
Aurpibul L; Cressey TR; Sricharoenchai S; Wittawatmongkol O; Sirisanthana V; Phongsamart W; Sudjaritruk T; Chokephaibulkit K
Pediatr Infect Dis J; 2015 Apr; 34(4):392-7. PubMed ID: 25760566
[TBL] [Abstract][Full Text] [Related]
3. Effect of Pregnancy and Concomitant Antiretrovirals on the Pharmacokinetics of Tenofovir in Women With HIV Receiving Tenofovir Disoproxil Fumarate-Based Antiretroviral Therapy Versus Women With HBV Receiving Tenofovir Disoproxil Fumarate Monotherapy.
Bukkems VE; Smolders EJ; Jourdain G; Burger DM; Colbers AP; Cressey TR;
J Clin Pharmacol; 2021 Mar; 61(3):388-393. PubMed ID: 32960984
[TBL] [Abstract][Full Text] [Related]
4. Pilot pharmacokinetic study of human immunodeficiency virus-infected patients receiving tenofovir disoproxil fumarate (TDF): investigation of systemic and intracellular interactions between TDF and abacavir, lamivudine, or lopinavir-ritonavir.
Pruvost A; Negredo E; Théodoro F; Puig J; Levi M; Ayen R; Grassi J; Clotet B
Antimicrob Agents Chemother; 2009 May; 53(5):1937-43. PubMed ID: 19273671
[TBL] [Abstract][Full Text] [Related]
5. Tenofovir clearance is reduced in HIV-positive patients with subclinical tubular impairment.
Calcagno A; Cusato J; Marinaro L; Simiele M; Lucchiari M; Alcantarini C; Tettoni MC; Trentini L; Mengozzi G; D'Avolio A; Di Perri G; Bonora S
AIDS; 2016 Mar; 30(6):915-20. PubMed ID: 26636928
[TBL] [Abstract][Full Text] [Related]
6. Steady-state amprenavir and tenofovir pharmacokinetics after coadministration of unboosted or ritonavir-boosted fosamprenavir with tenofovir disoproxil fumarate in healthy volunteers.
Luber AD; Condoluci DV; Slowinski PD; Andrews M; Olson K; Peloquin CA; Pappa KA; Pakes GE;
HIV Med; 2010 Mar; 11(3):193-9. PubMed ID: 19863619
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics and dosing recommendations of tenofovir disoproxil fumarate in hepatic or renal impairment.
Kearney BP; Yale K; Shah J; Zhong L; Flaherty JF
Clin Pharmacokinet; 2006; 45(11):1115-24. PubMed ID: 17048975
[TBL] [Abstract][Full Text] [Related]
8. A phase 1 randomized placebo-controlled safety and pharmacokinetic trial of a tenofovir disoproxil fumarate vaginal ring.
Keller MJ; Mesquita PM; Marzinke MA; Teller R; Espinoza L; Atrio JM; Lo Y; Frank B; Srinivasan S; Fredricks DN; Rabe L; Anderson PL; Hendrix CW; Kiser PF; Herold BC
AIDS; 2016 Mar; 30(5):743-51. PubMed ID: 26605514
[TBL] [Abstract][Full Text] [Related]
9. A randomized comparison of second-line lopinavir/ritonavir monotherapy versus tenofovir/lamivudine/lopinavir/ritonavir in patients failing NNRTI regimens: the HIV STAR study.
Bunupuradah T; Chetchotisakd P; Ananworanich J; Munsakul W; Jirajariyavej S; Kantipong P; Prasithsirikul W; Sungkanuparph S; Bowonwatanuwong C; Klinbuayaem V; Kerr SJ; Sophonphan J; Bhakeecheep S; Hirschel B; Ruxrungtham K;
Antivir Ther; 2012; 17(7):1351-61. PubMed ID: 23075703
[TBL] [Abstract][Full Text] [Related]
10. Factors associated with daily tenofovir exposure in Thai subjects taking combination antiretroviral therapy.
Kerr SJ; Punyawudho B; Thammajaruk N; Colbers A; Chaiyahong P; Phonphithak S; Sapsirisavat V; Ruxrungtham K; Burger DM; Avihingsanon A
AIDS Res Hum Retroviruses; 2015 Apr; 31(4):368-74. PubMed ID: 25384393
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics and safety of tenofovir disoproxil fumarate on coadministration with lopinavir/ritonavir.
Kearney BP; Mathias A; Mittan A; Sayre J; Ebrahimi R; Cheng AK
J Acquir Immune Defic Syndr; 2006 Nov; 43(3):278-83. PubMed ID: 17079992
[TBL] [Abstract][Full Text] [Related]
12. Greater tenofovir-associated renal function decline with protease inhibitor-based versus nonnucleoside reverse-transcriptase inhibitor-based therapy.
Goicoechea M; Liu S; Best B; Sun S; Jain S; Kemper C; Witt M; Diamond C; Haubrich R; Louie S;
J Infect Dis; 2008 Jan; 197(1):102-8. PubMed ID: 18171292
[TBL] [Abstract][Full Text] [Related]
13. Renal safety of lithium in HIV-infected patients established on tenofovir disoproxil fumarate containing antiretroviral therapy: analysis from a randomized placebo-controlled trial.
Decloedt EH; Lesosky M; Maartens G; Joska JA
AIDS Res Ther; 2017 Feb; 14(1):6. PubMed ID: 28160772
[TBL] [Abstract][Full Text] [Related]
14. Population pharmacokinetics of tenofovir in HIV-1-infected pediatric patients.
Bouazza N; Urien S; Hirt D; Frange P; Rey E; Benaboud S; Foissac F; Blanche S; Tréluyer JM
J Acquir Immune Defic Syndr; 2011 Nov; 58(3):283-8. PubMed ID: 21857359
[TBL] [Abstract][Full Text] [Related]
15. Renal Toxicity of Concomitant Exposure to Tenofovir and Inhibitors of Tenofovir's Renal Efflux Transporters in Patients Infected With HIV Type 1.
Rokx C; Alshangi H; Verbon A; Zietse R; Hoorn EJ; Rijnders BJ
J Infect Dis; 2016 Feb; 213(4):561-8. PubMed ID: 26401025
[TBL] [Abstract][Full Text] [Related]
16. InterPrEP: internet-based pre-exposure prophylaxis with generic tenofovir disoproxil fumarate/emtrictabine in London - analysis of pharmacokinetics, safety and outcomes.
Wang X; Nwokolo N; Korologou-Linden R; Hill A; Whitlock G; Day-Weber I; McClure MO; Boffito M
HIV Med; 2018 Jan; 19(1):1-6. PubMed ID: 28657199
[TBL] [Abstract][Full Text] [Related]
17. Tenofovir disoproxil fumarate co-administered with lopinavir/ritonavir is strongly associated with tubular damage and chronic kidney disease.
Mizushima D; Nguyen DTH; Nguyen DT; Matsumoto S; Tanuma J; Gatanaga H; Trung NV; van Kinh N; Oka S
J Infect Chemother; 2018 Jul; 24(7):549-554. PubMed ID: 29602711
[TBL] [Abstract][Full Text] [Related]
18. Steady-state amprenavir, tenofovir, and emtricitabine pharmacokinetics before and after reducing ritonavir boosting of a fosamprenavir/tenofovir/emtricitabine regimen from 200 mg to 100 mg once daily (TELEX II).
Parks DA; Jennings HC; Taylor C; Pakes GE; Acosta EP
HIV Clin Trials; 2009; 10(3):160-7. PubMed ID: 19632955
[TBL] [Abstract][Full Text] [Related]
19. HIV-1 genital shedding in HIV-infected patients randomized to second-line lopinavir/ritonavir monotherapy versus tenofovir/lamivudine/lopinavir/ritonavir.
Bunupuradah T; Bowonwattanuwong C; Jirajariyavej S; Munsakul W; Klinbuayaem V; Sophonphan J; Mahanontharit A; Hirschel B; Ruxrungtham K; Ananworanich J;
Antivir Ther; 2014; 19(6):579-86. PubMed ID: 24464590
[TBL] [Abstract][Full Text] [Related]
20. Higher tenofovir exposure is associated with longitudinal declines in kidney function in women living with HIV.
Baxi SM; Scherzer R; Greenblatt RM; Minkoff H; Sharma A; Cohen M; Young MA; Abraham AG; Shlipak MG;
AIDS; 2016 Feb; 30(4):609-18. PubMed ID: 26558723
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
